Publications by authors named "N Chereau"
Preoperative treatment of PHPT aims to 1) manage severe and/or symptomatic hypercalcemia and 2) prevent postoperative hypocalcemia. Severe hypercalcemia, defined as a blood calcium level ≥ 3.5 mmol/L, requires admission to hospital in a conventional or critical care unit, depending on clinical symptoms and comorbidities.
View Article and Find Full Text PDFBackground: The ATA guidelines suggest lobectomy as an option for select patients with thyroid cancer (TC), but some may need completion thyroidectomy because of unfavorable characteristics on the final pathology. This study aimed to compare postoperative morbidity of patients with TC who underwent total thyroidectomy in two steps (TT2) or one step (TT1).
Methods: This was a retrospective comparative study in a high-volume endocrine surgery center.
Article Synopsis
- The study analyzed patients from 2017 to 2022, comparing postoperative serum calcium levels and PTH levels taken shortly after the surgery to create a management algorithm involving calcium and alfacalcidol for those with low intraoperative PTH levels.
- Results showed that using intraoperative PTH levels improved prediction of symptomatic hypocalcemia significantly, identifying 90% of cases, while only 58% could be predicted using postoperative serum calcium levels alone.
The current dogma is a life-long follow-up for patients treated for follicular-derived differentiated thyroid cancers (DTC). Our primary objective was to determine the time to recurrence in a series of DTC patients with an excellent response to therapy 6 months after total thyroidectomy and radioiodine therapy. The secondary objectives were to determine the time to suspicion of recurrence and to identify factors associated with recurrence.
View Article and Find Full Text PDFPurpose: Risk factors for developing radioiodine refractory thyroid cancer (RAIR-TC) have rarely been analyzed. The purpose of the present study was to find clinical and pathological features associated with the occurrence of RAIR-disease in differentiated thyroid cancers (DTC) and to establish an effective predictive risk score.
Methods: All cases of RAIR-DTC treated in our center from 1990 to 2020 were retrospectively reviewed.